193 related articles for article (PubMed ID: 28903387)
1. Hyperactivated mTORC1 downregulation of FOXO3a/PDGFRα/AKT cascade restrains tuberous sclerosis complex-associated tumor development.
Wang L; Ni Z; Liu Y; Ji S; Jin F; Jiang K; Ma J; Ren C; Zhang H; Hu Z; Zha X
Oncotarget; 2017 Aug; 8(33):54858-54872. PubMed ID: 28903387
[TBL] [Abstract][Full Text] [Related]
2. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
4. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
5. Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex.
Ji S; Lin W; Wang L; Ni Z; Jin F; Zha X; Fei G
J Cancer; 2017; 8(4):555-562. PubMed ID: 28367235
[TBL] [Abstract][Full Text] [Related]
6. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.
Zhang H; Bajraszewski N; Wu E; Wang H; Moseman AP; Dabora SL; Griffin JD; Kwiatkowski DJ
J Clin Invest; 2007 Mar; 117(3):730-8. PubMed ID: 17290308
[TBL] [Abstract][Full Text] [Related]
7. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ
J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
[TBL] [Abstract][Full Text] [Related]
9. RUNX1/EGFR pathway contributes to STAT3 activation and tumor growth caused by hyperactivated mTORC1.
Lin W; Wan X; Sun A; Zhou M; Chen X; Li Y; Wang Z; Huang H; Li H; Chen X; Hua J; Zha X
Mol Ther Oncolytics; 2021 Dec; 23():387-401. PubMed ID: 34853810
[TBL] [Abstract][Full Text] [Related]
10. miR-125b-5p/STAT3 Pathway Regulated by mTORC1 Plays a Critical Role in Promoting Cell Proliferation and Tumor Growth.
Zhang C; Wan X; Tang S; Li K; Wang Y; Liu Y; Sha Q; Zha X; Liu Y
J Cancer; 2020; 11(4):919-931. PubMed ID: 31949495
[TBL] [Abstract][Full Text] [Related]
11. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
[TBL] [Abstract][Full Text] [Related]
12. Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.
Zucco AJ; Pozzo VD; Afinogenova A; Hart RP; Devinsky O; D'Arcangelo G
Mol Cell Neurosci; 2018 Oct; 92():149-163. PubMed ID: 30144504
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2
Jones AT; Narov K; Yang J; Sampson JR; Shen MH
Neoplasia; 2019 Feb; 21(2):230-238. PubMed ID: 30622053
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
15. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
Pal R; Xiong Y; Sardiello M
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
[TBL] [Abstract][Full Text] [Related]
16. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex proteins 1 and 2 control serum-dependent translation in a TOP-dependent and -independent manner.
Bilanges B; Argonza-Barrett R; Kolesnichenko M; Skinner C; Nair M; Chen M; Stokoe D
Mol Cell Biol; 2007 Aug; 27(16):5746-64. PubMed ID: 17562867
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex.
Kovalenko A; Sanin A; Kosmas K; Zhang L; Wang J; Akl EW; Giannikou K; Probst CK; Hougard TR; Rue RW; Krymskaya VP; Asara JM; Lam HC; Kwiatkowski DJ; Henske EP; Filippakis H
Cancer Res; 2021 Apr; 81(8):2086-2100. PubMed ID: 33593821
[TBL] [Abstract][Full Text] [Related]
19. Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis.
Filippakis H; Belaid A; Siroky B; Wu C; Alesi N; Hougard T; Nijmeh J; Lam HC; Henske EP
Sci Rep; 2018 Sep; 8(1):14161. PubMed ID: 30242175
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex.
Lu Y; Zhang EY; Liu J; Yu JJ
Orphanet J Rare Dis; 2020 Aug; 15(1):209. PubMed ID: 32807195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]